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ABSTRACT
microRNAs (miRNAs) are a versatile class of non-
coding RNAs involved in regulation of various bio-
logical processes. miRNA-122 (miR-122) is specifically
and abundantly expressed in human liver. In this
study, we employed 30-end biotinylated synthetic
miR-122 to identify its targets based on affinity puri-
fication. Quantitative RT-PCR analysis of the affinity
purified RNAs demonstrated a specific enrichment
of several known miR-122 targets such as CAT-1
(also called SLC7A1), ADAM17 and BCL-w. Using
microarray analysis of affinity purified RNAs, we
also discovered many candidate target genes of
miR-122. Among these candidates, we confirmed
that protein kinase, interferon-inducible double-
stranded RNA-dependent activator (PRKRA), a
Dicer-interacting protein, is a direct target gene of
miR-122. miRNA quantitative-RT–PCR results
indicated that miR-122 and small interfering RNA
against PRKRA may facilitate the accumulation of
newly synthesized miRNAs but did not detectably
affect endogenous miRNAs levels. Our findings will
lead to further understanding of multiple functions
of this hepato-specific miRNA. We conclude that
miR-122 could repress PRKRA expression and fa-
cilitate accumulation of newly synthesized miRNAs.
INTRODUCTION
MicroRNAs (miRNAs) are small conserved RNAs of
 22nt which negatively modulate gene expression in
animals and plants, primarily through base paring to the
30-untranslated region (UTR) of target messenger RNAs
(mRNAs). This leads to mRNA cleavage and/or
translation repression (1). miRNAs are primarily
transcribed by RNA polymerase II as part of capped
and polyadenylated primary transcripts (pri-miRNAs)
that can be either protein-coding or non-coding. The
primary transcript is cleaved by Drosha ribonuclease III
enzyme to produce an  70-nt stem–loop precursor
miRNA (pre-miRNA), which is further cleaved by the
cytoplasmic Dicer ribonuclease to generate the mature
miRNA. The mature miRNA is incorporated into an
RNA-induced silencing complex (RISC), which recognizes
target mRNAs through imperfect base pairing with the
miRNA. Bioinformatic analysis predicts that each
miRNA may regulate hundreds of target genes, suggesting
that miRNAs may play a role in almost every biological
pathway (2). Indeed, miRNAs have been implicated in the
regulation of various cellular processes, including cell pro-
liferation, apoptosis and stress responses (3–6).
One of the ﬁrst clues of the existence of miRNAs in
mammals came from studies on genetic alterations in
woodchuck liver tumors. In 1989, a gene rearrangement
of c-myc and an unusual transcript, named hcr, was desc-
ribed in one of these tumors. This transcript was char-
acterized as liver speciﬁc, essentially non-coding,
speciﬁcally nuclear and processed by endonucleases (7).
Furthermore, hcr was proposed to be the precursor for
miR-122. In the current understanding, the part of the
hcr transcript encompassing the so-called ‘pri-miRNA’ is
predicted to be processed to form a 66-nt long ‘pre-
miRNA’, which presents a hairpin structure with 79%
base pairing, and which will ultimately be cleaved by the
endonuclease Dicer to form the mature miR-122 (8).
Recent works on tissue-speciﬁc miRNAs has demon-
strated miRNAs participation in tissue speciﬁcation and
cell lineage decisions (9–11). Among these tissue-speciﬁc
miRNAs, miR-122 is one which is speciﬁcally expressed in
adult liver and constitutes 70% of the total miRNA popu-
lation (12–14). Recent studies showed that miR-122 could
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(HCV) replication (17–19), apoptosis (20) and play a
role in hepatocellular carcinoma (HCC) (21–23). To
better understand the role of this liver-speciﬁc miRNA,
the identiﬁcation of the target genes of miR-122 is
necessary.
In the present study, we employed 30-end biotinylated
synthetic miR-122 to identify its target genes based on afﬁn-
ity puriﬁcation as described previously (24,25). Quantitative
reverse transcriptase–polymerase chain reaction (RT–PCR)
analysis of the afﬁnity puriﬁed RNAs demonstrated a
speciﬁc enrichment of several reported miR-122 targets,
such as CAT-1 (13), ADAM17 (22) and BCL-w (20). By
microarray, many candidate target genes of miR-122 were
identiﬁed. We also veriﬁed that PRKRA, which showed a
high of enrichment in afﬁnity puriﬁcation assay, was a
new target gene of miR-122. Furthermore, the
over-expression of miR-122 could facilitate the accumula-
tion of newly synthesized miRNA.
MATERIALS AND METHODS
Cell lines and cultures
HepG2 and HeLa cell lines were cultured in DMEM
(GIBCO BRL, Grand Island, NY, USA) containing
10% FBS with 100U/ml penicillin and 100mg/ml strepto-
mycin at 37 C with 5% CO2.
Afﬁnity puriﬁcation experiments
To identify mRNAs associated with miRNA-122, afﬁnity
puriﬁcation experiments were performed as described pre-
viously (Supplementary Figure S1, see Supplementary
Methods for details) (24,25). Synthetic miRNA-122
duplexes were produced carrying a biotin group attached
to the 30-end of the miRNA sense strand (TaKaRa,
Dalian, China) and transfected into HepG2 cells. Cells
were harvested 48h after transfection. The isolated RNA
was ready for downstream qRT–PCR or microarray
analysis.
Real-time qRT–PCR for mRNA
Total RNA was isolated using TRI Reagent (Sigma-
Aldrich, St Louis, USA). cDNA was generated by
reverse transcription using 1mg of total RNA
and ImProm-II
TM Reverse Transcription System
(Promega, Madison, WI, USA). Quantitative real-time
PCR was performed on the MX 3000P
TM PCR
Instrument (Stratagene, La Jolla, USA) using SYBR
Premix EX Taq
TM (TaKaRa). Forward (F) and
reverse (R) primers used were as follows: GAPDH-
F5 0-tcagtggtggacctgacctg-30, GAPDH-R 50-tgctgtagccaa-
attcgttg-30; BCL-w -F 50-tttggttcggctttatcagg-30, BCL-w-R
50-gaggactgcgagttccaaag-30; CAT-1-F 50-ggctgtcctctggtga-
gaag-30, CAT-1-R 50-ggccaccagatcaaaagtgt-30; ADAM-
17-F 50-ctgtggtgcaaaagcagaaa-30, ADAM-17-R 50-tgcca-
aatgcctcatattca-30; PRKRA-F 50-acgaatacggcatgaagacc-30,
PRKRA-R 50-tggaagggtcaggcattaag-30; A20-F 50-
gagagcacaatggctgaaca-30, A20-R 50-tccagtgtgta
tcggtgcat-30.
Microarray hybridization
RNA from afﬁnity puriﬁcation experiments was linear
ampliﬁed (Two-Cycle Eukaryotic Target Labeling Kit,
P/N 900494, Affymetrix, Inc., Santa Clara, CA, USA)
and analyzed on Affymetrix human u133 plus 2.0 micro-
arrays, which include a set of human maintenance genes to
facilitate the normalization and scaling of array experi-
ments. This set of genes serves as a tool to normalize
and scale the data prior to performing data comparisons.
miRNA target site analysis
Affymetrix probe set identiﬁers were mapped to Ensembl
transcripts using the Ensembl Biomart system. The
30-UTR sequences were extracted from Ensembl using
Biomart utilities. UltraEdit software was used to search
candidate 30-UTR for seed matches (perfect Watson–
Crick matches between the 6-mer from bases 2 to 7 of
the miRNA from the 50-end) with none or one of three
kinds of extensions: (i) an A across from nucleotide 1 in
the miRNA (seedM+t1A), (ii) an additional match be-
tween the site and nucleotide 8 in the miRNA
(seedM+m8M) and (iii), the combination of (i) and
(ii) (seedM+m8M+t1A). TargetScan software (www
.targetscan.org) was used to search for conserved miR-
122-binding sites.
Plasmid construction
For the expression of miR-122, miR-133 or miR-30a,
genomic fragment of Homo sapiens miR-122, miR-133
or miR-30a precursor was ampliﬁed and cloned into
pcDNA3.0 (Invitrogen, Carlsbad, CA, USA). PRKRA
30-UTR segment was subcloned into the pGL3 Control
vector (Promega) immediately downstream of the stop
codon of the luciferase gene. PCR with the appropriate
primers also generated inserts with point substitutions in
the miRNA complementary sites. Wild-type and mutant
inserts were conﬁrmed by sequencing.
miRNA qRT–PCR
For miRNA detection, total RNA was polyadenylated by
poly (A) polymerase (Ambion, Austin, USA). An amount
of 50ml polyadenylation reaction was set up with 10mg
total RNA and 1ml (2U) poly (A) polymerase according
to the manufacturer’s protocol. After incubation at 37 C
for 60min, poly (A)-tailed total RNA was recovered by
phenol/chloroform extraction and ethanol precipitation.
RT reaction was performed using 1mg poly (A) tailed
total RNA and 1mg RT primer [50-gcgagcacagaattaata
cgatcactatagg(t)18VN-30] with 1ml ImProm-II
TM Reverse
Transcriptase (Promega) according to the manufacturer’s
protocol. qPCR was performed as described in the method
of Quantitect SYBR Green PCR Kit (Qiagen, Hilden,
Germany) with Mx3000p
TM (Stratagene) supplied with
analytical software. One primer of miRNA
ampliﬁcation is miRNA speciﬁc (miR-122 50-tggagtgt
gacaatggtgtttg-30; miR-16 50-tagcagcacgtaaatattggcg-30;
miR-24 50-tggctcagttcagcaggaacag-30; miR-133 50-tttggtcc
ccttcaaccagctg-30; miR-30a 50-tgtaaacatcctcgactggaag-30),
and the other is a universal primer (50-gcgagcacagaa
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tion (U6-F 50-cgcttcggcagcacatatacta-30; U6-R 50-cgcttcac
gaatttgcgtgtca-30).
miRNAs, small interfering RNAs and transfection
The miR-122 duplex and PRKRA small interfering RNAs
(siRNAs) were designed and synthesized by GenePharma
(GenePharma, Shanghai, China). The sequences of miRNA
duplex and siRNAs were presented in Supplementary
Table S1. siRNAs and miRNAs were transfected using
Lipofectamine 2000 (Invitrogen). In brief, cells were
cultured in a six-well plate to 50% conﬂuence. For each
well, 5ml siRNA (20mM) or miRNA (20mM) was added
into 250ml Opti-MEM medium (GIBCO BRL), 4mlo f
Lipofectamine 2000 into 250ml Opti-MEM medium and
then mixed siRNA or miRNA with Lipofectamine 2000
after 5min incubation. After 20min, the mixture was
added to cells and incubated for 6h before replacing the
medium. Total RNA and protein were prepared 48 or 72h
after transfection and were used for qRT–PCR or western
blotting analysis.
Western blot
Total cell lysate was prepared in 1  SDS buffer. Proteins
at the same amount were separated by SDS–PAGE and
transferred onto PVDF membranes. After probing
with anti-PRKRA (10771-1-AP; Protein Tech Group,
Inc., Chicago, USA) or anti-b-actin antibody (Beijing
Zhongshan Biotechnology, Beijing, China) and incubating
with proper secondary antibody, antigen–antibody
complex was visualized by enhanced chemiluminescence’s
reagents Supersignal (Pierce, Rochford, IL, USA).
Luciferase reporter assay
Adherent HepG2 cells were grown in DMEM with 10%
FBS to 80–90% conﬂuency in 24-well plates. Cells were
co-transfected with 100ng of ﬁreﬂy luciferase reporter
vector containing the PRKRA 30-UTR (named pGL3-
PRKRA-30-UTR) or PRKRA mutant (named pGL3-
PRKRA-30-UTRmut) and 8ng of the control vector
containing Renilla luciferase, pRL-TK (Promega), in a
ﬁnal volume of 0.5ml using Lipofectamine 2000
(Invitrogen). Fireﬂy and Renilla luciferase activities were
measured consecutively using the Dual-luciferase assays
(Promega) 48h after transfection.
Statistic analysis
All data are presented as means SD. Differences were
assessed by two-tailed Student’s t-test using Excel
software. P<0.05 was considered to be statistically
signiﬁcant.
RESULTS
Afﬁnity puriﬁcation of miR-122 target mRNAs
To identify mRNA targets of miR-122, we employed
an afﬁnity-based target-identiﬁcation procedure in which
miR-122 is synthesized with a 30-biotin group allowing for
subsequent puriﬁcation with streptavidin (Supplementary
Figure S1). This technique has been previously veriﬁed for
afﬁnity puriﬁcation of miRNA targets in Drosophila
melanogaster cells and human neuronal cells (24,25). We
validated the technique using a biotin-tagged miR-122 tar-
geting several reported targets such as CAT-1 (13),
ADAM17 (22) and BCL-w (20). Afﬁnity puriﬁcation ex-
periments in HepG2 cells resulted in a 2- to 19-fold en-
richment of these endogenous targets (Figure 1).
To identify more targets of miR-122, RNAs from afﬁn-
ity puriﬁcation experiment were linear ampliﬁed and
analyzed on microarrays. Microarray results showed
that 1474 genes were enriched >2-fold by 30-biotin
modiﬁed miR-122 (output) compared with total RNA
(input) (Supplementary Table 2). We examined the
30-UTRs for the presence of the 6-nt sequence CACTCC
, which is the reverse complement of the nucleotides 2–7
seed in the mature miR-122 sequence. About 39% of the
enriched mRNAs having at least one miR-122 recognition
sequence, while the seed match frequency in all annotated
human 30-UTRs was only 25%, implying that a signiﬁcant
pool of the enriched mRNAs correspond to direct
miR-122 targets in the liver (P<0.001, Figure 2B and
Supplementary Table S3). Detailed studies indicate that
the presence of extended seed matches increases the like-
lihood that a given message is regulated by a miRNA
(26,27). We therefore examined the identiﬁed seed
matches for the presence of an A anchor corresponding
to the 50 most nucleotide of miR-122, as well as for an
extended match to base 8 of miR-122 as described by
Lewis et al. (26). Both the 7-nt and the 8-nt seed matches
were signiﬁcantly enriched in our microarray data
(Figure 2Aand B; Supplementary Table S3). Moreover,
about one-third of the conserved targets predicted by
TargetScan software showed >2-fold of enrichment by
biotin modiﬁed miR-122 (38 out of 124, Supplementary
Table S2).
The GO analysis revealed that the enriched genes were
over represented in gene categories involved in cellular
functions associated with the regulation of transcription
and RNA splicing, as well as development and cell
cycle (Supplementary Table S4 and See Supplementary
Table S5 for details).
Interaction between miR-122 and the 30-UTR
of PRKRA mRNA
In previously mentioned afﬁnity puriﬁcation experiment,
PRKRA showed a high-level enrichment ( 45-fold) and
harbored one putative binding site for miR-122 in its
mRNA’s 30-UTR which was conserved across various spe-
cies (Figure 3A). To investigate the potential miRNA:
mRNA interaction, the human PRKRA 30-UTR was
subcloned after the ﬁreﬂy luciferase open reading frame
(ORF) and cotransfected into HepG2 cells with the
miR-122 duplex, which could mimic miR-122 molecule.
miR-122 duplex could lead to a 60% decrease of relative
luciferase activity compared with Negative Control trans-
fected cells (Figure 3B). An analogous reporter with point
substitutions disrupting the target sites (as illustrated,
Figure 3A) was also contransfected with miR-122
duplex. There was no decrease of relative luciferase activity
886 Nucleic Acids Research, 2012,Vol. 40,No. 2in miR-122 duplex transfected cells compared with
Negative Control transfected cells (Figure 3B).
PRKRA is a potential target of miR-122
To learn whether miR-122 can affect endogenous
PRKRA, we examined the impact of this miR-122 on
PRKRA protein expression in cultured cells. Western
blot from protein extracts obtained from the HepG2
cells revealed dramatically reduction in PRKRA protein
level after miR-122 duplex transfection (Figure 3C). In
contrast, negative control-transfected cells showed no re-
duction in PRKRA protein level. Because inhibition of
expression by miRNA may also be mediated by mRNA
degradation (28,29), we examined whether the PRKRA
mRNA levels might be affected by miR-122. Figure 3D
showed the PRKRA mRNA level was dramatically
reduced by miR-122 duplex (42% reduction). Taken
together, afﬁnity puriﬁcation experiment, luciferase data,
immunoassay and real-time qRT–PCR assay provided
strong evidences that PRKRA is a target of miR-122.
miR-122 facilitates accumulation of newly synthesized
miRNA through downregulate PRKRA
PRKRA (PACT) cDNA was cloned by virtue of its inter-
action with PKR (30). PRKRA is a human cellular
protein that heterodimerizes with PKR through its
double-stranded RNA-binding domains (dsRBDs) and
activates PKR pathway in vitro and in vivo in the absence
of dsRNA. In contrast to PRKRA, the human immuno-
deﬁciency virus transactivating response RNA-binding
protein (TRBP), another dsRBD protein with 42%
identity to PRKRA, has an inhibitory effect on PKR
(31). The opposite effects of PRKRA and TRBP on
PKR activity are mediated by the C-terminal dsRBDs,
which are devoid of detectable dsRNA-binding properties
(31). PRKRA and TRBP have been demonstrated recently
to interact with RNase III Dicer, a key enzyme involving
in miRNA maturation, through their C-terminal dsRBDs
(32–35). By using siRNA against TRBP, Chendrimada
et al. (32) found that TRBP knockdown reduced endogen-
ous miRNA levels in cell culture, whereas Haase et al. (33)
saw no such reduction.
To assess the potential role of PRKRA in miRNA
pathway, we transfected HeLa cells with miR-122 duplex
or siRNAs against PRKRA. Via miRNA-RT–qPCR, we
found the endogenous levels of miR-16 and miR-24
changed only slightly after the depletion of PRKRA
(Figure 4A and B). This supports the previous observation
that mature miRNA is highly stable in cells and therefore
the changes in the steady-state level of mature miRNA
may be difﬁcult to detect (36–38). Then we cotransfected
miR-133 expressing vector (pcDNA3.0-miR133) with
miR-122 duplex or siRNAs against PRKRA into HeLa
cells. Results from miRNA-RT–qPCR indicated that
miR-122 duplex, siPRKRA-1 and siPRKRA-2 could fa-
cilitate accumulation of newly synthesized miR-133
(Figure 4C). We also found that PRKRA siRNAs could
also facilitate accumulation of newly synthesized miR-122
when HeLa cells were cotransfected with miR-122 express-
ing vector (pcDNA3.0-miR122) (Figure 4D). Similar
results were observed in HepG2 cell line (data not
shown). To monitor PKR activity, we analysis the expres-
sion of Tnfaip3 (A20) which could be induced by PKR
activation through NF-kB pathway (39,40). Real time
qRT–PCR results showed that downregulation of
PRKRA by siRNA has no effect on A20 expression
(Supplementary Figure S3). Our ﬁndings that PRKRA
Figure 1. Afﬁnity puriﬁcation with biotin-tagged miR-122 from human hepatoma HepG2 cells and quantitative RT–PCR for its endogenous target
CAT-1, ADAM17 and BCL-w. HepG2 cells were treated with cell lysis buffer 48h after transfection. Data were normalized to the level of GAPDH
mRNA. Results of the mean of triplicate quantitative PCR assays with standard deviation of the mean are presented. *P<0.05.
Figure 2. A signiﬁcant enrichment of miR-122 targets by biotin-tagged
miR-122. (A) Different seed types of miR-122. (B) The occurrence of
miR-122 6-, 7- or 8-nt seed sequence matches in biotin-miR-122
enriched mRNAs (grey columns) and in all human annotated genes
(white columns).
Nucleic AcidsResearch, 2012, Vol.40,No. 2 887knockdown facilitated accumulation of newly synthesized
miRNA support the hypothesis that PRKRA and TRBP
have opposite effects on miRNA maturation just like the
situation in PKR pathway (Figure 5).
DISCUSSION
The present study shows that PRKRA could be enriched
by 30-biotin modiﬁed miR-122. It is also shown that
PRKRA is negatively regulated by miR-122 via a
speciﬁc target site within the 30-UTR. Moreover, we
showed that miR-122 facilitates accumulation of newly
synthesized miRNA through downregulating PRKRA ex-
pression. The identiﬁcation of miR-122 as an important
regulator of miRNA maturation emphasizes an essential
role of this liver-speciﬁc miRNA.
Sophisticated mechanisms regulating RNA may explain
the gap between the great complexity of cellular functions
and the limited number of primary transcripts. Regulation
by miRNAs underscores this possibility, as each miRNA
is believed to bind directly to many mRNAs to regulate
their translation or stability and thereby control a wide
range of activities. Despite their biological importance,
determining the targets of miRNAs is a major challenge.
Attention has largely been laid on computational predic-
tions of targets based on the observation that many
miRNAs can recognize their targets by binding to motifs
in the 30-UTR sequences complementary to bases 2–8 of
the miRNA (the seed region) (41). Whereas these algo-
rithms have been instrumental in many studies of individ-
ual miRNA:mRNA interactions, unbiased approaches to
study miRNA target recognition are important to discover
new features of miRNAs. In this study, we used a direct
afﬁnity-based procedure to isolate target mRNAs bound
by miR-122. These results will help us to understand the
function of this liver-speciﬁc miRNA. While preparing
this manuscript one group has published a paper
demonstrating miR-122 targeting CUTL1 (CUX1)
during liver development, which is also enriched by
biotin-tagged miR-122 (Supplementary Table S2) (42).
The afﬁnity-based target-identiﬁcation procedure was
performed following Orom et al. (24,25) with some
Figure 3. miR-122 inhibits PRKRA expression. (A upper panel) The target site of miR-122 in PRKRA 30-UTR is conserved among mammalian
species. (A lower panel) Predicted duplex formation between miR-122 and the targeted PRKRA 30-UTR. The PRKRA 30-UTR mutant is identical
with the wild-type except that its three point substitutions disrupting pairing to miR-122 seed. (B) pGL3-PRKRA-30-UTR reporter plasmid in which
the luciferase-coding sequence had been fused to the 30-UTR of PRKRA was cotransfected into HepG2 cells with Negative Control (grey columns)
or miR-122 duplex (white columns). Luciferase activity was normalized relative to a simultaneously transfected Renilla expression plasmid.
30-UTR-Mut indicates the introduction of alterations into the seed complementary sites shown in Figure 3A. Results of the mean of quadruplicate
assays with standard deviation of the mean are presented. *P<0.05. (C) Western blots of PRKRA from HepG2 cells. Cells were transfected with
Negative Control or miR-122 duplex. Cells were harvested 48h later, and 30mg of whole-cell lysate was added into each lane. A b-actin antibody was
used in a reprobing as a loading control. (D) Real-time RT–PCR of PRKRA in HepG2 cells transfected with the Negative Control or miR-122
duplex for 48h. Data were normalized to the level of GAPDH mRNA. Results of the mean of triplicate qPCR assays with standard deviation of the
mean are presented. *P<0.05.
888 Nucleic Acids Research, 2012,Vol. 40,No. 2modiﬁcation. The non-speciﬁc binding of RNAs to
streptavidin–agarose beads was unavoidable even we
washed the beads four times with cell lysis buffer.
Therefore, GAPDH with no putative target site of miR-
122 was chosen to serve as an internal control. If one gene
is the target of miR-122, the output would contain
more mRNA/GAPDH than the Input. To validate our
results, we also normalize mRNA with b-actin (no
putative target site of miR-122 in its 30-UTR). Results
from real-time PCR showed that miR-122’s known tar-
get gene had enrichment in Ouput when normalized
to GAPDH or b-actin (Figure 1 and Supplementary
Figure S4).
miRNAs are generated by a two-step processing path-
way. Primary miRNAs are processed to pre-miRNAs by
Drosha. These pre-miRNAs are cleaved by Dicer to
generate mature miRNAs (43–45). In human cells,
Drosha exists as part of a protein complex called the
Microprocessor complex, which contains the dsRNA-
binding protein DGCR8 (also called Pasha). DGCR8 is
essential for Drosha activity and capable of binding single-
stranded fragments of the pri-miRNA that are required
for proper processing (46,47). Dicer also exists as part of a
protein complex which contains two dsRNA-binding
proteins, TRBP and PRKRA (32–35). It was reported that
TRBP knockdown reduced endogenous miRNA levels in
cell culture (32). Here, we found that PRKRA knockdown
by miR-122 duplex or siRNAs against PRKRA could fa-
cilitate accumulation of newly synthesized miRNA. Thus
dsRNA-binding protein such as DGCR8, TRBP and
PRKRA could affect the miRNAs processing pathway
by interacting with Drosha or Dicer.
However, our ﬁnding that PRKRA is a negative regu-
lator of miRNA processing is in direct conﬂict with the
ﬁnding of Lee et al. (34). They demonstrated that the re-
duction of PRKRA protein results in reduced miRNA
accumulation. The contradictory results probably re-
ﬂect the different methodologies. Lee et al. depleted
PRKRA by RNAi from a HeLa cell line that expresses
pri-miR-30a from the tetracycline-inducible promoter.
After incubation with siRNA, the cell line was exposed
to doxycycline, the derivative of tetracycline, for induc-
tion of pri-miR-30a. By using northern blotting on
miR-30a, they found that reduction of PRKRA protein
levels results in reduced miRNA accumulation. While
we co-transfected siRNA and miRNA-expressing vector
into HeLa cell line. By using miRNA quantitative-
RT–PCR, we found that PRKRA siRNAs could facilitate
the accumulation of miRNA. Moreover, we co-transfected
PRKRA siRNAs and miR-30a-expressing vector (the
speciﬁc miRNA investigated by Lee et al.) into HeLa
cell line. Forty-eight hours after transfection, we employed
Figure 4. miR-122 facilitates the accumulation of newly synthesized miRNA through regulating PRKRA. (A and B) miRNA-RT–qPCR detected the
expression of miR-16 and miR-24. HeLa cells were transfected with the Negative Control siRNA, miR-122 duplex, siPRKRA-1 or siPRKRA-2 for
48h. (C) miRNA-RT–qPCR detected the expression of miR-133. HeLa cells were cotransfected with miR-133 expressing vector (pcDNA3.0-miR133)
and Negative Control siRNA, miR-122 duplex, siPRKRA-1 or siPRKRA-2 for 48h. (D) The same experiment as described in (C), except for
cotransfecting HeLa cells with miR-122 expressing vector (pcDNA3.0-miR122) and Negative Control siRNA, siPRKRA-1 or siPRKRA-2 for 48h.
Total RNA was poly-A tailed, reverse transcripted and then real-time PCR tested. Data were normalized to the level of U6 RNA. Results of the
mean of triplicate quantitative PCR assays with standard deviation of the mean are presented.
Nucleic AcidsResearch, 2012, Vol.40,No. 2 889miRNA quantitative-RT–PCR to detect miR-30a ex-
pression and found that PRKRA siRNAs could also fa-
cilitate the accumulation of miR-30a (Supplementary
Figure S5).
An interesting paradox exists between TRBP and
PRKRA, which shares 42% amino acid sequence identity.
TRBP inhibits the dsRNA-activated PKR, whereas
PRKRA activates this protein—both using their
C-terminal domains for these functions (31). TRBP and
PRKRA could interact with Dicer, raising the intriguing
possibility that TRBP and PRKRA modulate PKR differ-
entially in response to dsRNAs in the cytoplasm. For
instance, it would be disadvantageous to the cell to have
miRNA precursors activating PKR, as this may ultimately
lead to cell death. Thus, our ﬁndings suggest that TRBP
and PRKRA might be responsible for keeping the balance
between PKR pathway and pre-miRNA processing
(Figure 5).
In conclusion, miR-122, a hepato-speciﬁc miRNA,
inhibits the expression of Dicer-interacting PRKRA gene
by binding to the 30-UTR of PRKRA mRNA and thereby
facilitates the accumulation of newly synthesized miRNA.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary material, Supplementary tables, Supple-
mentary ﬁgures 1–5.
FUNDING
Chinese State Key Projects for Basic Research
(2010CB912801, 2007CB914601); partially by grants
from Chinese Key Project for the Infectious Diseases
(2008ZX10002-016); and Chinese National Natural
Science Foundation (30870529, 30873008). Funding for
open access charge: Chinese State Key Projects for Basic
Research (2010CB912801).
Conﬂict of interest statement. None declared.
REFERENCES
1. Bartel,D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism,
and function. Cell, 116, 281–297.
2. Krek,A., Grun,D., Poy,M.N., Wolf,R., Rosenberg,L.,
Epstein,E.J., MacMenamin,P., da Piedade,I., Gunsalus,K.C.,
Stoffel,M. et al. (2005) Combinatorial microRNA target
predictions. Nat. Genet., 37, 495–500.
3. Xu,P., Guo,M. and Hay,B.A. (2004) MicroRNAs and the
regulation of cell death. Trends Genet., 20, 617–624.
4. Cheng,A.M., Byrom,M.W., Shelton,J. and Ford,L.P. (2005)
Antisense inhibition of human miRNAs and indications for
an involvement of miRNA in cell growth and apoptosis.
Nucleic Acids Res., 33, 1290–1297.
5. Felli,N., Fontana,L., Pelosi,E., Botta,R., Bonci,D., Facchiano,F.,
Liuzzi,F., Lulli,V., Morsilli,O., Santoro,S. et al. (2005)
MicroRNAs 221 and 222 inhibit normal erythropoiesis and
erythroleukemic cell growth via kit receptor down-modulation.
Proc. Natl Acad. Sci. USA, 102, 18081–18086.
6. Dresios,J., Aschraﬁ,A., Owens,G.C., Vanderklish,W.,
Edelman,G.M. and Mauro,V.P. (2005) Cold stress-induced
protein Rbm3 binds 60S ribosomal subunits, alters
microRNA levels, and enhances global protein synthesis.
Proc. Natl Acad. Sci. USA, 102, 1865–1870.
7. Moroy,T., Etiemble,J., Bougueleret,L., Hadchouel,M., Tiollais,P.
and Buendia,M.A. (1989) Structure and expression of hcr, a locus
rearranged with c-myc in a woodchuck hepatocellular carcinoma.
Oncogene, 4, 59–65.
8. Chang,J., Provost,P. and Taylor,J.M. (2003) Resistance of human
hepatitis delta virus RNAs to dicer activity. J. Virol., 77,
11910–11917.
9. Liang,Y., Ridzon,D., Wong,L. and Chen,C. (2007)
Characterization of microRNA expression proﬁles in normal
human tissues. BMC Genomics, 8, 166.
10. Chen,J.F., Mandel,E.M., Thomson,J.M., Wu,Q., Callis,T.E.,
Hammond,S.M., Conlon,F.L. and Wang,D.Z. (2006) The role of
microRNA-1 and microRNA-133 in skeletal muscle proliferation
and differentiation. Nat. Genet., 38, 228–233.
11. Lim,L.P., Lau,N.C., Garrett-Engele,P., Grimson,A., Schelter,J.M.,
Castle,J., Bartel,D.P., Linsley,P.S. and Johnson,J.M. (2005)
Microarray analysis shows that some microRNAs downregulate
large numbers of target mRNAs. Nature, 433, 769–773.
12. Lagos-Quintana,M., Rauhut,R., Yalcin,A., Meyer,J.,
Lendeckel,W. and Tuschl,T. (2002) Identiﬁcation of tissue-speciﬁc
microRNAs from mouse. Curr. Biol., 12, 735–739.
13. Chang,J., Nicolas,E., Marks,D., Sander,C., Lerro,A.,
Buendia,M.A., Xu,C., Mason,W.S., Moloshok,T., Bort,R. et al.
(2004) miR-122, a mammalian liver-speciﬁc microRNA, is
processed from hcr mRNA and may downregulate the high
afﬁnity cationic amino acid transporter CAT-1. RNA Biol., 1,
106–113.
14. Randall,G., Panis,M., Cooper,J.D., Tellinghuisen,T.L.,
Sukhodolets,K.E., Pfeffer,S., Landthaler,M., Landgraf,P., Kan,S.,
Lindenbach,B.D. et al. (2007) Cellular cofactors affecting hepatitis
C virus infection and replication. Proc. Natl Acad. Sci. USA, 104,
12884–12889.
15. Krutzfeldt,J., Rajewsky,N., Braich,R., Rajeev,K.G., Tuschl,T.,
Manoharan,M. and Stoffel,M. (2005) Silencing of microRNAs
in vivo with ‘antagomirs’. Nature, 438, 685–689.
16. Esau,C., Davis,S., Murray,S.F., Yu,X.X., Pandey,S.K., Pear,M.,
Watts,L., Booten,S.L., Graham,M., McKay,R. et al. (2006)
miR-122 regulation of lipid metabolism revealed by in vivo
antisense targeting. Cell Metab., 3, 87–98.
17. Jopling,C.L., Yi,M., Lancaster,A.M., Lemon,S.M. and Sarnow,P.
(2005) Modulation of hepatitis C virus RNA abundance by a
liver-speciﬁc MicroRNA. Science, 309, 1577–1581.
Figure 5. The regulation of miRNA maturation and PKR pathway by
TRBP and PRKRA. PRKRA and TRBP involved in the regulation of
PKR pathway and the maturation of miRNAs through interacting with
PKR or Dicer, respectively.
890 Nucleic Acids Research, 2012,Vol. 40,No. 218. Henke,J.I., Goergen,D., Zheng,J., Song,Y., Schuttler,C.G.,
Fehr,C., Junemann,C. and Niepmann,M. (2008) microRNA-122
stimulates translation of hepatitis C virus RNA. EMBO J., 27,
3300–3310.
19. Lanford,R.E., Hildebrandt-Eriksen,E.S., Petri,A., Persson,R.,
Lindow,M., Munk,M.E., Kauppinen,S. and Orum,H. (2010)
Therapeutic silencing of microRNA-122 in primates with chronic
hepatitis C virus infection. Science, 327, 198–201.
20. Lin,C.J., Gong,H.Y., Tseng,H.C., Wang,W.L. and Wu,J.L. (2008)
miR-122 targets an anti-apoptotic gene, Bcl-w, in human
hepatocellular carcinoma cell lines. Biochem. Biophys. Res.
Commun., 375, 315–320.
21. Kutay,H., Bai,S., Datta,J., Motiwala,T., Pogribny,I., Frankel,W.,
Jacob,S.T. and Ghoshal,K. (2006) Downregulation of miR-122
in the rodent and human hepatocellular carcinomas.
J. Cell Biochem., 99, 671–678.
22. Tsai,W.C., Hsu,P.W., Lai,T.C., Chau,G.Y., Lin,C.W., Chen,C.M.,
Lin,C.D., Liao,Y.L., Wang,J.L., Chau,Y.P. et al. (2009)
MicroRNA-122, a tumor suppressor microRNA that regulates
intrahepatic metastasis of hepatocellular carcinoma. Hepatology,
49, 1571–1582.
23. Bai,S., Nasser,M.W., Wang,B., Hsu,S.H., Datta,J., Kutay,H.,
Yadav,A., Nuovo,G., Kumar,P. and Ghoshal,K. (2009)
MicroRNA-122 inhibits tumorigenic properties of hepatocellular
carcinoma cells and sensitizes these cells to sorafenib.
J. Biol. Chem., 284, 32015–32027.
24. Orom,U.A. and Lund,A.H. (2007) Isolation of microRNA targets
using biotinylated synthetic microRNAs. Methods, 43, 162–165.
25. Orom,U.A., Nielsen,F.C. and Lund,A.H. (2008) MicroRNA-10a
binds the 50UTR of ribosomal protein mRNAs and enhances
their translation. Mol. Cell, 30, 460–471.
26. Lewis,B.P., Burge,C.B. and Bartel,D.P. (2005) Conserved seed
pairing, often ﬂanked by adenosines, indicates that thousands of
human genes are microRNA targets. Cell, 120, 15–20.
27. Grimson,A., Farh,K.K., Johnston,W.K., Garrett-Engele,P.,
Lim,L.P. and Bartel,D.P. (2007) MicroRNA targeting speciﬁcity
in mammals: determinants beyond seed pairing. Mol. Cell, 27,
91–105.
28. Lim,L.P., Lau,N.C., Garrett-Engele,P., Grimson,A., Schelter,J.M.,
Castle,J., Bartel,D.P., Linsley,P.S. and Johnson,J.M. (2005)
Microarray analysis shows that some microRNAs downregulate
large numbers of target mRNAs. Nature, 433, 769–773.
29. Bagga,S., Bracht,J., Hunter,S., Massirer,K., Holtz,J., Eachus,R.
and Pasquinelli,A.E. (2005) Regulation by let-7 and lin-4
miRNAs results in target mRNA degradation. Cell, 122, 553–563.
30. Patel,R.C. and Sen,G.C. (1998) PACT, a protein activator of the
interferon-induced protein kinase, PKR. EMBO J., 17,
4379–4390.
31. Gupta,V., Huang,X. and Patel,R.C. (2003) The carboxy-terminal,
M3 motifs of PACT and TRBP have opposite effects on PKR
activity. Virology, 315, 283–291.
32. Chendrimada,T.P., Gregory,R.I., Kumaraswamy,E., Norman,J.,
Cooch,N., Nishikura,K. and Shiekhattar,R. (2005) TRBP recruits
the Dicer complex to Ago2 for microRNA processing and gene
silencing. Nature, 436, 740–744.
33. Haase,A.D., Jaskiewicz,L., Zhang,H., Laine,S., Sack,R.,
Gatignol,A. and Filipowicz,W. (2005) TRBP, a regulator of
cellular PKR and HIV-1 virus expression, interacts with Dicer
and functions in RNA silencing. EMBO Rep., 6, 961–967.
34. Lee,Y., Hur,I., Park,S.Y., Kim,Y.K., Suh,M.R. and Kim,V.N.
(2006) The role of PACT in the RNA silencing pathway.
EMBO J., 25, 522–532.
35. Kok,K.H., Ng,M.H., Ching,Y.P. and Jin,D.Y. (2007) Human
TRBP and PACT directly interact with each other and associate
with dicer to facilitate the production of small interfering RNA.
J. Biol. Chem., 282, 17649–17657.
36. Lee,Y., Ahn,C., Han,J., Choi,H., Kim,J., Yim,J., Lee,J.,
Provost,P., Radmark,O., Kim,S. et al. (2003) The nuclear
RNase III Drosha initiates microRNA processing. Nature, 425,
415–419.
37. Yi,R., Qin,Y., Macara,I.G. and Cullen,B.R. (2003) Exportin-5
mediates the nuclear export of pre-microRNAs and short hairpin
RNAs. Genes Dev., 17, 3011–3016.
38. Lund,E., Guttinger,S., Calado,A., Dahlberg,J.E. and Kutay,U.
(2004) Nuclear export of microRNA precursors. Science, 303,
95–98.
39. Lee,E.G., Boone,D.L., Chai,S., Libby,S.L., Chien,M., Lodolce,J.P.
and Ma,A. (2000) Failure to regulate TNF-induced NF-kappaB
and cell death responses in A20-deﬁcient mice. Science, 289,
2350–2354.
40. Donze,O., Deng,J., Curran,J., Sladek,R., Picard,D. and
Sonenberg,N. (2004) The protein kinase PKR: a molecular
clock that sequentially activates survival and death programs.
EMBO J., 23, 564–571.
41. Bartel,D.P. (2009) MicroRNAs: target recognition and regulatory
functions. Cell, 136, 215–233.
42. Xu,H., He,J.H., Xiao,Z.D., Zhang,Q.Q., Chen,Y.Q., Zhou,H. and
Qu,L.H. (2010) Liver-enriched transcription factors regulate
microRNA-122 that targets CUTL1 during liver development.
Hepatology, 52, 1431–1442.
43. Grishok,A., Pasquinelli,A.E., Conte,D., Li,N., Parrish,S., Ha,I.,
Baillie,D.L., Fire,A., Ruvkun,G. and Mello,C.C. (2001) Genes
and mechanisms related to RNA interference regulate expression
of the small temporal RNAs that control C. elegans
developmental timing. Cell, 106, 23–34.
44. Hutvagner,G., McLachlan,J., Pasquinelli,A.E., Balint,E., Tuschl,T.
and Zamore,P.D. (2001) A cellular function for the
RNA-interference enzyme Dicer in the maturation of the let-7
small temporal RNA. Science, 293, 834–838.
45. Ketting,R.F., Fischer,S.E., Bernstein,E., Sijen,T., Hannon,G.J.
and Plasterk,R.H. (2001) Dicer functions in RNA interference
and in synthesis of small RNA involved in developmental timing
in C. elegans. Genes Dev., 15, 2654–2659.
46. Denli,A.M., Tops,B.B., Plasterk,R.H., Ketting,R.F. and
Hannon,G.J. (2004) Processing of primary microRNAs by the
Microprocessor complex. Nature, 432, 231–235.
47. Han,J., Lee,Y., Yeom,K.H., Nam,J.W., Heo,I., Rhee,J.K.,
Sohn,S.Y., Cho,Y., Zhang,B.T. and Kim,V.N. (2006) Molecular
basis for the recognition of primary microRNAs by the
Drosha-DGCR8 complex. Cell, 125, 887–901.
Nucleic AcidsResearch, 2012, Vol.40,No. 2 891